ClinicalTrials.gg
TerminatedNCT05633745Updated Oct 26, 2023

A Study to Assess NEU-723 in Healthy Participants

A Phase 1 interventional study of NEU-723 and Placebo in Healthy, sponsored by Neuron23 Inc.. Terminated at 1 site in New Zealand. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-26.

Sponsored by Neuron23 Inc. · Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), multiple ascending dose (MAD), of orally administered NEU-723 in healthy subjects.

Read the detailed description

Up to five (5) single-ascending oral doses will be administered to 40 healthy adult male or female subjects (aged 18-80 years, inclusive). Escalation to the next higher dose level may occur only after evaluation of the safety and PK results of the previous dose level (at least 6 evaluable subjects). Within each cohort, 6 subjects will receive one dose of NEU-723, and 2 subjects will receive one dose of matching placebo. Dose levels may be revised based on available safety and PK data.

Multiple ascending oral doses will be administered up to 24 healthy subjects (aged 18 - 80 years, inclusive) in 3 sequential dosing groups (8 subjects in each dosing group). Six (6) subjects will receive NEU-723 and two (2) subjects will receive matching placebo in each dosing group (cohort) for 7 days. Escalation to the next higher dose level may occur only after evaluation of the safety and PK results of the previous dose level (at least 6 evaluable subjects). Dose levels may be revised based on available safety and PD data.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Neuron23 Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects for standard cohorts must be 18-80 years, inclusive, at the time of signing the ;
  2. Subjects who are in good general health with no abnormalities based on the medical history, physical examinations, neurological examinations, clinical laboratory evaluations (hematology and clinical chemistry)
  3. Subjects who have a (BMI) of 18-32 kg/m2(inclusive);
  4. Male subjects are eligible to participate if they are rendered surgically sterile (at least 6 months), or agree to the following during the study and for at least 30 days after the last dose of study drug:

    • Refrain from donating sperm;

    AND, either:

    • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; OR
    • Agree to use a male condom (/barrier) and should also be advised of the benefit for a female partner to use an acceptable, highly effective method of contraception as a condom may break or leak when having sexual intercourse;
  5. Female subjects are eligible to participate if they are not pregnant or breastfeeding, subject to one of the following:

    • Women of (WOCBP), defined as women physiologically capable of becoming pregnant, must have a negative serum pregnancy test at the Screening visit and a negative urine pregnancy test on Day -1; WOCBP must agree to use an acceptable, highly effective contraceptive method from Screening until 30 days after the last dose of study treatment (see Section 11.3); OR
    • Menopausal women must have an elevated serum follicle-stimulating hormone level (FSH) level at Screening; if the FSH is not elevated, they are considered to be of childbearing potential (unless permanently sterile) and must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1;

Exclusion criteria

Exclusion Criteria:

  1. History of hematological, renal, pancreatic, gastrointestinal, hepatic, cardiovascular, metabolic, endocrine, immunological, allergic disease, or other major disorders
  2. History of clinically significant abnormal chest x-ray
  3. Clinically significant neurologic disorder
  4. to undergo a lumbar puncture (only for subjects participating in the MAD)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    NEU-723

    Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (7 days)

    Drug: NEU-723

  • Placebo comparator
    Placebo

    Part A: Single-ascending dose cohorts; Part B: Multiple-ascending dose cohorts (7 days)

    Drug: Placebo

Interventions

  • DrugNEU-723

    Oral Doses

  • DrugPlacebo

    Oral Doses

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability of single and multiple oral doses of NEU-723 in healthy subjects

    Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 7 days of dosing

Secondary outcomes

  1. PK Parameter

    The maximum concentration (Cmax) at steady state in plasma

    Time frame: Up to 7 days of dosing

  2. PK Parameter

    The area under the concentration-time curve from zero to infinity (AUC0-inf) in plasma

    Time frame: Up to 7 days of dosing

  3. PK Parameter

    The time to reach maximum concentration (tmax) in plasma

    Time frame: Up to 7 days of dosing

  4. PK Parameter

    Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC\[0-last\]) in plasma

    Time frame: Up to 7 days of dosing

  5. PK Parameter

    Apparent terminal elimination half-life (t1/2) in plasma

    Time frame: Up to 7 days of dosing

  6. PK Parameter

    The terminal elimination rate constant (λZ) with the respective half-life (t½) in plasma

    Time frame: Up to 7 days of dosing

  7. PK Parameter

    The oral clearance (CL/F)

    Time frame: Up to 7 days of dosing

  8. PK Parameter

    The volume of distribution (Vd/F)

    Time frame: Up to 7 days of dosing

  9. PK Parameter

    The area under the concentration-time curve over a dosing interval (AUC0-τ) in plasma (multiple dosing only)

    Time frame: Up to 7 days of dosing

07

Study locations

1 site
  • New Zealand Clinical Research
    Christchurch, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jun 2023, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2022
First posted
Dec 1, 2022
StartActual
Jan 30, 2023
Primary completionActual
Jun 30, 2023
CompletionActual
Jun 30, 2023
Last update
Oct 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05633745
Lead sponsor
Neuron23 Inc.
Responsible party
Sponsor
First posted
Dec 1, 2022
Start date
Jan 30, 2023
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Oct 26, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion